Leukocyte colony-stimulating factors. A review of associated XXXX and vasculitides.

@entity1 @entity6794 @entity1333 @entity203 @entity7250 @entity262 @entity272
BACKGROUND: Hematopoietic colony-stimulating factors are a diverse group of cytokines now commercially available through recombinant technology. The colony-stimulating factors have proven utility in a wide spectrum of cytopenic states, and their use is now common-place. Unlike many cytokines, the colony-stimulating factors are usually well tolerated. We present a dramatic case of @entity6794 arising during granulocyte colony-stimulating factor therapy. Additionally, the relevant literature regarding cutaneous complications of colony-stimulating factor therapy is summarized. OBSERVATIONS: Including our case, two reported @entity1 developed @entity6794 while under colony-stimulating factor therapy. @entity7250 presented in an additional three @entity1 , and @entity1333 was precipitated in three others. The @entity203 consistently developed after 1 to 2 weeks of colony-stimulating factor therapy and were apparently unrelated to the underlying @entity262 . Although most reactions developed de novo, three were superimposed on a preexisting inflammatory process. CONCLUSIONS: Serious cutaneous adverse effects of colony-stimulating factors are distinctly rare but include @entity272 and @entity1333 . Upregulation of neutrophilic function and secondary release of cytokines may induce these complications. Early recognition and cessation of colony-stimulating factor therapy will limit the morbidity of these adverse events.
